Search research articles
Contact Us
Filters
Showing results (11-20 of 22) with videos related to
Page
of 3
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 21, 2023
A Composite Decision Rule of CD8+ T-cell Density in Tumor Biopsies Predicts Efficacy in Early-stage, Immunotherapy Trials
David Dejardin, Anton Kraxner, Annika Blank, et al.
Cancer
|
June 19, 2009
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R)
Hagop Kantarjian, Ricardo Pasquini, Vincent Lévy, et al.
Journal for Immunotherapy of Cancer
|
January 16, 2026
Biomarkers of activity from a phase I study of cergutuzumab amunaleukin in patients with advanced solid tumors
Ignacio Melero, Neeltje Steeghs, Ulrik Lassen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 17, 2024
Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors
Neeltje Steeghs, Carlos Gomez-Roca, Kristoffer S Rohrberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 18, 2024
Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma
Aaron R Hansen, Carlos A Gomez-Roca, Debbie G J Robbrecht, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 6, 2024
Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors
Solange Peters, Eric Angevin, Teresa Alonso-Gordoa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 18, 2025
Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen-Positive Advanced/Metastatic Solid Tumors
Ignacio Melero, Josep Tabernero, Neeltje Steeghs, et al.
Cancer Research Communications
|
February 3, 2025
Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma
Eva Munoz-Couselo, Ainara Soria Rivas, Shahneen Sandhu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 27, 2026
Phase I Study of Mosperafenib, a Novel Paradox Breaker B-Raf Proto-Oncogene Serine/Threonine Kinase (BRAF) Inhibitor, in Patients With <i>BRAF</i> V600-Mutant Solid Tumors
Maria Vieito, Elisa Fontana, Catherine H Han, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 6, 2024
Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal Cancer
Hans Prenen, Sanjeev Deva, Bhumsuk Keam, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 22) with videos related to
Sort By:
Page
of 3
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 21, 2023
A Composite Decision Rule of CD8+ T-cell Density in Tumor Biopsies Predicts Efficacy in Early-stage, Immunotherapy Trials
David Dejardin, Anton Kraxner, Annika Blank, et al.
Cancer
|
June 19, 2009
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R)
Hagop Kantarjian, Ricardo Pasquini, Vincent Lévy, et al.
Journal for Immunotherapy of Cancer
|
January 16, 2026
Biomarkers of activity from a phase I study of cergutuzumab amunaleukin in patients with advanced solid tumors
Ignacio Melero, Neeltje Steeghs, Ulrik Lassen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 17, 2024
Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors
Neeltje Steeghs, Carlos Gomez-Roca, Kristoffer S Rohrberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 18, 2024
Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma
Aaron R Hansen, Carlos A Gomez-Roca, Debbie G J Robbrecht, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 6, 2024
Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors
Solange Peters, Eric Angevin, Teresa Alonso-Gordoa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 18, 2025
Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen-Positive Advanced/Metastatic Solid Tumors
Ignacio Melero, Josep Tabernero, Neeltje Steeghs, et al.
Cancer Research Communications
|
February 3, 2025
Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma
Eva Munoz-Couselo, Ainara Soria Rivas, Shahneen Sandhu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 27, 2026
Phase I Study of Mosperafenib, a Novel Paradox Breaker B-Raf Proto-Oncogene Serine/Threonine Kinase (BRAF) Inhibitor, in Patients With <i>BRAF</i> V600-Mutant Solid Tumors
Maria Vieito, Elisa Fontana, Catherine H Han, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 6, 2024
Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal Cancer
Hans Prenen, Sanjeev Deva, Bhumsuk Keam, et al.
Page
of 3